Haemonetics
269 hedge funds and large institutions have $5.05B invested in Haemonetics in 2020 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 84 increasing their positions, 104 reducing their positions, and 69 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
2.16% more ownership
Funds ownership: 98.64% → 100.81% (+2.2%)
10% less funds holding
Funds holding: 298 → 269 (-29)
12% less call options, than puts
Call options by funds: $12.1M | Put options by funds: $13.7M
12% less capital invested
Capital invested by funds: $5.74B → $5.05B (-$693M)
19% less repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 104
38% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 69
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$97.5M |
| 2 |
EC
Eminence Capital
New York
|
+$60.4M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$56.2M |
| 4 |
AAMU
AEGON Asset Management (UK)
Edinburgh,
United Kingdom
|
+$54.3M |
| 5 |
Goldman Sachs
New York
|
+$50.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$312M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$43.3M |
| 3 |
Morgan Stanley
New York
|
-$38.1M |
| 4 |
Renaissance Technologies
New York
|
-$27.7M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$20.1M |
HAE Hedge Fund Activity: Q1 2020 in Review
269 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2020, worth a combined $5.05B — down 12% from $5.74B a quarter earlier.
Sellers outnumbered buyers: 69 funds closed out of HAE and 43 opened new positions — a net loss of 26 holders — while 104 trimmed existing stakes and 84 added.
The largest buyer was HealthCor Management, adding an estimated $97.5M. The largest seller was Wellington Management Group, cutting an estimated $312M.
- 269 institutional investors held Haemonetics (HAE) as of Q1 2020, down from 298 in Q4 2019.
- Funds reported $5.05B of Haemonetics stock for Q1 2020, down 12% quarter-over-quarter.
- 43 funds opened new Haemonetics positions in Q1 2020 and 69 closed out, a net change of -26 holders.
- The largest Haemonetics buyer in Q1 2020 was HealthCor Management, an estimated $97.5M added.
- The largest Haemonetics seller in Q1 2020 was Wellington Management Group, an estimated $312M sold.
Based on aggregated 13F filings for Q1 2020.